GRADE guidelines: 2. Framing the question and deciding on important outcomes

被引:921
作者
Guyatt, Gordon H. [1 ]
Oxman, Andrew D. [2 ]
Kunz, Regina [3 ]
Atkins, David [4 ]
Brozek, Jan [1 ]
Vist, Gunn [2 ]
Alderson, Philip [5 ]
Glasziou, Paul [6 ]
Falck-Ytter, Yngve [7 ]
Schuenemann, Holger J. [1 ]
机构
[1] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada
[2] Norwegian Knowledge Ctr Hlth Serv, Oslo, Norway
[3] Univ Basel Hosp, Acad Swiss Insurance Med, CH-4031 Basel, Switzerland
[4] US Dept Vet Affairs, Off Res & Dev, Washington, DC USA
[5] Natl Inst Hlth & Clin Excellence, Ctr Clin Practice, Manchester, Lancs, England
[6] Bond Univ, Gold Coast, Qld, Australia
[7] Case Western Reserve Univ, Div Gastroenterol, Case & VA Med Ctr, Cleveland, OH 44106 USA
关键词
GRADE; PICO; Patient-important outcomes; Surrogate; Guideline development; Quality of evidence; Indirectness; PATIENT-IMPORTANT OUTCOMES; ATRIAL-FIBRILLATION; CONTROLLED-TRIALS; CLINICAL-TRIALS; METAANALYSIS; THERAPY;
D O I
10.1016/j.jclinepi.2010.09.012
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
100404 [儿少卫生与妇幼保健学];
摘要
GRADE requires a clear specification of the relevant setting, population, intervention, and comparator. It also requires specification of all important outcomes whether evidence from research studies is, or is not, available. For a particular management question, the population, intervention, and outcome should be sufficiently similar across studies that a similar magnitude of effect is plausible. Guideline developers should specify the relative importance of the outcomes before gathering the evidence and again when evidence summaries are complete. In considering the importance of a surrogate outcome, authors should rate the importance of the patient-important outcome for which the surrogate is a substitute and subsequently rate down the quality of evidence for indirectness of outcome. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:395 / 400
页数:6
相关论文
共 17 条
[1]
[Anonymous], J CLIN EPID IN PRESS
[2]
Fracture prevention with vitamin D supplementation - A meta-analysis of randomized controlled trials [J].
Bischoff-Ferrari, HA ;
Willett, WC ;
Wong, JB ;
Giovannucci, E ;
Dietrich, T ;
Dawson-Hughes, B .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (18) :2257-2264
[3]
Increased cancer-related mortality for patients with type 2 diabetes who use sulforrylureas or insulin [J].
Bowker, SL ;
Majumdar, SR ;
Veugelers, P ;
Johnson, JA .
DIABETES CARE, 2006, 29 (02) :254-258
[4]
Bucher H, 2008, USERS GUIDES MED LIT
[5]
Effect of HMGcoA reductase inhibitors on stroke - A meta-analysis of randomized, controlled trials [J].
Bucher, HC ;
Griffith, LE ;
Guyatt, GH .
ANNALS OF INTERNAL MEDICINE, 1998, 128 (02) :89-+
[6]
Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes [J].
Deeks, JJ .
STATISTICS IN MEDICINE, 2002, 21 (11) :1575-1600
[7]
Guidelines for anticoagulant use in acute coronary syndromes [J].
Eikelboom, John ;
Guyatt, Gordon ;
Hirsh, Jack .
LANCET, 2008, 371 (9624) :1559-1561
[8]
Can we individualize the "number needed to treat"? An empirical study of summary effect measures in meta-analyses [J].
Furukawa, TA ;
Guyatt, GH ;
Griffith, LE .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2002, 31 (01) :72-76
[9]
Patient-important outcomes in registered diabetes trials [J].
Gandhi, Gunjan Y. ;
Murad, M. Hassan ;
Fujiyoshi, Akira ;
Mullan, Rebecca J. ;
Flynn, David N. ;
Elamin, Mohamed B. ;
Swiglo, Brian A. ;
Isley, William L. ;
Guyatt, Gordon H. ;
Montori, Victor M. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (21) :2543-2549
[10]
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) [J].
Gent, M ;
Beaumont, D ;
Blanchard, J ;
Bousser, MG ;
Coffman, J ;
Easton, JD ;
Hampton, JR ;
Harker, LA ;
Janzon, L ;
Kusmierek, JJE ;
Panak, E ;
Roberts, RS ;
Shannon, JS ;
Sicurella, J ;
Tognoni, G ;
Topol, EJ ;
Verstraete, M ;
Warlow, C .
LANCET, 1996, 348 (9038) :1329-1339